Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
General Rheumatology
•
Biologics
•
Immunosuppression
•
DMARD
Are there specific combinations of DMARDs and/or biologics that you avoid due to elevated infection risk or other safety concerns?
Related Questions
In a patient with negative Hep B surface Ag, Hep B surface antibody+, and Hep B core antibody+ serologies, do you initiate antiviral prophylaxis (e.g. entecavir) prior to starting rituximab?
How do you handle medication refills for patients on traditional DMARDs who are lost to follow-up?
In light of recent measles outbreaks, have you adjusted your vaccination counseling or preventive strategies for adult immunocompromised patients?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
In an elderly male with recurrent unilateral exudative pleural effusion, +ANA 1:1280, homogeneous and +anti-Smith antibody, but no other lupus features, how do you decide between escalating immunosuppression versus pursuing pleurodesis?
How do you guide patients who seek online information about their disease to ensure it is accurate, supports their understanding, and minimizes unnecessary anxiety?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
Are there specific conventional DMARDs and/or biologics that are contraindicated in patients with alpha-gal allergy?
How do you counsel patients with postural orthostatic tachycardia syndrome (POTS) regarding safe and effective exercise regimens?
Do you avoid JAK inhibitors in patients with antiphospholipid antibodies and/or lupus anticoagulant given the potential risk of increased thromboembolic events with use of JAKi?
